scholarly journals Options for Screening for Colorectal Cancer in the Royal Air Force: A Cost-effectiveness Evaluation

1995 ◽  
Vol 141 (3) ◽  
pp. 142-150 ◽  
Author(s):  
K. Daniels ◽  
M. McKee
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Air Force ◽  
Effectiveness Evaluation ◽  
Royal Air Force

A cost-effectiveness evaluation of newborn hemoglobinopathy screening in Alaska

1996 ◽  
Author(s):  
Bradford D. Gessner ◽  
Steven M. Teutsch ◽  
Phaedra A. Shaffer
Keyword(s):  
Cost Effectiveness ◽  
Effectiveness Evaluation

The Royal Air Force: Budget Preparation, Control & Execution

2020 ◽  
Author(s):  
Syeda Noor-ul-Huda Shahid ◽  
Usman W. Chohan
Keyword(s):  
Air Force ◽  
Royal Air Force

scholarly journals Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population

2021 ◽  
pp. 1-1
Author(s):  
Deborah A. Fisher ◽  
Jordan J. Karlitz ◽  
Sushanth Jeyakumar ◽  
Nathaniel Smith ◽  
Paul Limburg ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Colorectal Cancer Screening ◽  
Real World ◽  
Medicare Population

scholarly journals Correction to: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chun-Yi Lu ◽  
Ching-Hu Chung ◽  
Li-Min Huang ◽  
Eliza Kruger ◽  
Seng-Chuen Tan ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Haemophilus Influenzae ◽  
Conjugate Vaccine ◽  
Effectiveness Evaluation

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kiyoaki Sugiura ◽  
Yuki Seo ◽  
Takayuki Takahashi ◽  
Hideyuki Tokura ◽  
Yasuhiro Ito ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Health Care ◽  
Sensitivity Analysis ◽  
Cost Effectiveness ◽  
Combination Therapy ◽  
Metastatic Colorectal Cancer ◽  
Cost Effective ◽  
Model Parameters ◽  
Combination Regimen ◽  
The Cost

Abstract Background TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monotherapy for patients with chemorefractory metastatic colorectal cancer. Method Markov decision modeling using treatment costs, disease-free survival, and overall survival was performed to examine the cost-effectiveness of TAS-102 plus bevacizumab combination therapy and TAS-102 monotherapy. The Japanese health care payer’s perspective was adopted. The outcomes were modeled on the basis of published literature. The incremental cost-effectiveness ratio (ICER) between the two treatment regimens was the primary outcome. Sensitivity analysis was performed and the effect of uncertainty on the model parameters were investigated. Results TAS-102 plus bevacizumab had an ICER of $21,534 per quality-adjusted life-year (QALY) gained compared with TAS-102 monotherapy. Sensitivity analysis demonstrated that TAS-102 monotherapy was more cost-effective than TAS-102 and bevacizumab combination therapy at a willingness-to-pay of under $50,000 per QALY gained. Conclusions TAS-102 and bevacizumab combination therapy is a cost-effective option for patients who have metastatic colorectal cancer in the Japanese health care system.

Sign in / Sign up

Export Citation Format

Share Document